Shire clinches $32bn takeover of Baxalta

London-listed pharmaceuticals firm secures cash and stock deal after appeal to Baxalta shareholders

Shire, the London-listed drugs company, has agreed to buy Baxaltafor $ 32bn (£22bn) after receiving assurances that it will not face a big tax bill in the US by including cash in its bid.

The agreement caps Shire’s six-month pursuit of Baxalta, which was lengthened by tax complications. Shire, which is based in Dublin for tax purposes and managed in Boston, appealled to Baxalta’s shareholders to push for a deal after the board of the rare disease specialist turned down an approach worth $ 45.23 per share.

Continue reading…
Pharmaceuticals industry | The Guardian

Pharmaceutical Stocks


© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us